View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
April 12, 2011

Cerapedics Reports Positive Results from Bone Graft Study

Cerapedics has reported positive results from the trial of its i-Factor biologic bone graft for patients undergoing posterior lumbar interbody fusion spine procedures. At six and 12 months after treatment, data from 40 patients demonstrated superiority of i-Factor biologic bone graft o

By cms admin

Cerapedics has reported positive results from the trial of its i-Factor biologic bone graft for patients undergoing posterior lumbar interbody fusion spine procedures.

At six and 12 months after treatment, data from 40 patients demonstrated superiority of i-Factor biologic bone graft over autologous bone.

The radiological fusion rate was 97.7% for patients treated with i-Factor, compared to 59.1% for patients treated with autograft.

The prospective, randomised, controlled trial was designed to evaluate the safety and efficacy of the i-Factor biologic bone graft compared to autologous bone delivered via interbody fusion cages in single and multi-level posterior lumbar interbody fusion surgery.

All patients served as their own control and also received posterior pedicle screw instrumentation.

The i-Factor technology combines anorganic bone mineral and synthetic small peptide P-15 to form an attachment factor for specific integrins on osteogenic cells.

Cerapedics’ i-Factor biologic bone graft received European CE Mark in late 2008, and is currently being evaluated in the US.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management